

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/064808 A1

(51) International Patent Classification:

A61K 47/18 (2006.01) *A61K 47/68* (2017.01)
A61K 47/26 (2006.01) *A61K 9/08* (2006.01)
A61K 38/18 (2006.01) *A61K 9/19* (2006.01)

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/077968

(22) International Filing Date:

12 October 2022 (12.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/255,286 13 October 2021 (13.10.2021) US

(71) Applicant: **AKERO THERAPEUTICS, INC.** [US/US];
601 Gateway Blvd., Suite 350, South San Francisco, CA
94080 (US).

(72) Inventors: **DIMITROVA, Mariana, N.**; 601 Gateway
Blvd., Suite 350, South San Francisco, CA 94080 (US).
ROLPH, Timothy, P.; 601 Gateway Blvd., Suite 350,
South San Francisco, CA 94080 (US).

(74) Agent: **KISSLING, Heather, R.**; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower,
Chicago, IL 60606 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) Title: PHARMACEUTICAL COMPOSITIONS OF EFRUXIFERMIN

(57) Abstract: The disclosure provides pharmaceutical compositions comprising Efruxifermin, processes for preparing lyophilized compositions, and methods of use for treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFL), alcoholic steatohepatitis (ASH), alcoholic liver disease (ALD) or alcoholic fatty liver disease (AFL), type 2 diabetes, obesity, hypertriglyceridemia, dyslipidemia, protein misfolding disease, alcohol-related and other cravings or addictions, reversing liver cirrhosis or reducing fibrosis associated with NASH, ASH, ALD AFL, or protein misfolding disease, normalizing liver fat content, reducing elevated blood glucose, increasing insulin sensitivity, and/or reducing uric acid levels.



WO 2023/064808 A1